The use of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and diclofenac, has not been associated with any adverse effects in those who have tested positive for it. COVID-19According to a new study published today (September 8, 2020) PLOS therapy From Anton Pöttgaard and colleagues of the University of Southern Denmark Aarhus University Hospital and Danish Medicine Agency.
During the early stages of the COVID-19 epidemic, concerns were raised that the use of painkiller ibuprofen may lead to a more severe course of coronovirus disease. Since the use of ibuprofen and other NSAIDs is widespread, data on their safety is urgently needed to guide physicians and patients. In the new study, researchers obtained data on all 9,326 Danish residents who tested positive for it SARS-CoV-2 Viruses between February 27, 2020 and April 29, 2020. Data on NSAID use, 30-day mortality, hospitalization, ICU admission, mechanical ventilation and acute renal replacement therapy were available. 248 people (2.7%) had filled out a prescription for NSAIDs within 30 days of their positive virus test.
Researchers found no association between any of the results and NSAID use. Among NSAID users in the matchoff cohort who tested positive for coronovirus, 6.3% (95% confidence interval) [CI] 3.1–9.4) died, 24.5% (95% CI 18.6–30.4) hospitalized and 4.9% (95% CI 2.1–7.8) admitted to the ICU. Among those who tested positive for coronavirus, were not treated with NSAIDs, 6.1% (95% CI 4.4–7.8) died, 21.2% (95% CI 18.1–24.3) were hospitalized, and 4.7 % (95% 3.2-6.2.2)) were admitted in ICU. Neither of these differences between groups was statistically significant (mortality risk ratio [RR] 1.02, 95% CI 0.57–1.82, p = 0.95; Hospitalization RR 1.16, 95% CI 0.87–1.53, p = 0.31; ICU admission RR 1.04, 95% CI 0.54–2.02, p = 0.90).
“Considering the available evidence, there is no reason to withdraw the well-indicated use of NSAIDs during the SARS-CoV-2 epidemic,” the authors say. “However, the well-established adverse effects of NSAIDs, particularly their renal, gastrointestinal, and cardiac effects, should always be considered, and NSAIDs should be used in the lowest possible dose for all patients.”
Reference: “Adverse outcomes and mortality in non-steroidal anti-inflammatory drug users who tested positive for SARS-CoV-2: a Danish nationwide study” Lund LC, Christensen KB, Releins M, Christenson S, Thomson RW, CF by Christian, et al., 8 September 2020, PLOS therapy.
DOI: 10.1371 / journal.pmed.1003308